Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus

Nathan P. Wiederhold, Laura K. Najvar, Rosie Jaramillo, Marcos Olivo, Brian L. Wickes, Gabriel Catano, Thomas F. Patterson

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


We evaluated extended-interval dosing of the investigational echinocandin rezafungin (1, 4, and 16 mg/kg on days 1, 4, and 7 postinoculation) for the treatment of disseminated invasive aspergillosis caused by azole-resistant Aspergillus fumigatus. Survival was significantly improved in mice treated with each dose of rezafungin and supratherapeutic posaconazole (20 mg/kg twice daily). Kidney fungal burden, as measured by quantitative real-time PCR, was also significantly reduced in mice treated with rezafungin although variability was observed.

Original languageEnglish (US)
Article numbere01165-19
JournalAntimicrobial agents and chemotherapy
Issue number10
StatePublished - 2019


  • Aspergillus fumigatus
  • Azole resistance
  • Invasive aspergillosis
  • Murine model
  • Rezafungin
  • TR34/L98H

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology


Dive into the research topics of 'Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus'. Together they form a unique fingerprint.

Cite this